Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain
Rosa M. Jiménez-Rodríguez(Hospital Universitario Virgen del Rocío), José Miguel Cisneros(Hospital Universitario Virgen del Rocío), Sílvia Gómez-Zorrilla(Hospital Universitario Virgen del Rocío), Silvia Jiménez‐Jorge(Instituto de Salud Carlos III), Jaume Bonnin-Pascual(Hospital Universitario Son Espases), Clara Rosso-Fernández(Instituto de Biomedicina de Sevilla), José Antonio López-Ruiz(Hospital Universitario Virgen del Rocío), Julián Torre‐Cisneros(Instituto de Salud Carlos III), Cristina Roca-Oporto, Guillermo Martín-Gutiérrez(Hospital Universitario Virgen del Rocío), José Miguel Montejo(Hospital de Cruces), Luis Tallón‐Aguilar(Hospital Universitario Virgen Macarena), Alison Luckey(Global Antibiotic Research & Development Partnership), Lucía Boix-Palop, Ángela Cano(Hospital Universitario Reina Sofía)
Cited by 2
Related Papers
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia
|American Journal of Transplantation|2019|31
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28